395 related articles for article (PubMed ID: 17507664)
21. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
[TBL] [Abstract][Full Text] [Related]
24. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
Pule MA; Savoldo B; Myers GD; Rossig C; Russell HV; Dotti G; Huls MH; Liu E; Gee AP; Mei Z; Yvon E; Weiss HL; Liu H; Rooney CM; Heslop HE; Brenner MK
Nat Med; 2008 Nov; 14(11):1264-70. PubMed ID: 18978797
[TBL] [Abstract][Full Text] [Related]
25. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
27. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
Huls MH; Rooney CM; Heslop HE
Acta Haematol; 2003; 110(2-3):149-53. PubMed ID: 14583675
[TBL] [Abstract][Full Text] [Related]
28. Coexpression of major histocompatibility complex class I and LMP1 in Epstein-Barr virus-positive Hodgkin's lymphoma in a pediatric age group.
Aybar A; Krause JR
Microsc Res Tech; 2005 Nov; 68(3-4):247-9. PubMed ID: 16276512
[TBL] [Abstract][Full Text] [Related]
29. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
[TBL] [Abstract][Full Text] [Related]
30. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
31. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
32. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
34. Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.
Hong B; Peng G; Berry L; Gottschalk S; Jung JU; Chen SY; Huang XF
Gene Ther; 2012 Aug; 19(8):818-27. PubMed ID: 22052242
[TBL] [Abstract][Full Text] [Related]
35. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
36. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
Bollard CM; Cooper LJ; Heslop HE
Best Pract Res Clin Haematol; 2008 Sep; 21(3):405-20. PubMed ID: 18790446
[TBL] [Abstract][Full Text] [Related]
38. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
39. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.
Kim LH; Eow GI; Peh SC; Poppema S
Pathology; 2003 Oct; 35(5):428-35. PubMed ID: 14555388
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
